ElectroCore launches gammaCore Sapphire migraine treatment device

ElectroCore announced that it has launched its gammaCore Sapphire non-invasive vagus nerve stimulator in the U.S. The device is the first non-invasive vagus nerve stimulator device to be cleared by the FDA for acute treatment of pain from migraines and episodic cluster headaches. The gammaCore Sapphire device is portable and easy-to-use and can be self-administered

How SABIC helped develop a non-drug migraine treatment

SABIC recently helped eNeura develop a clinically proven, non-drug option for preventing and treating migraine headaches. The sTMS mini from eNeura is a portable delivery system for single-pulse, transcranial magnetic stimulation. It’s prescribed by a physician. FDA cleared the sTMS mini for migraine prevention in 2017. SABIC’s polycarbonate copolymer Lexan was chosen as the housing of

How modern medicine changed ancient antidotes

Modern medicine is revolutionary in comparison to how different diseases and disorders were treated in ancient times. Without regulation, its no surprise that methods like drilling a hole in the skull to relieve a headache and using enemas to treat asthma were normal practice. With the FDA’s founding in 1906, many devices and practices have

Medtech stories we missed this week: June 30, 2017

From ConforMIS touting its knee replacement study to Consulting Radiologists’s new breast cancer detection tool, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Study: Low-dose CT scanning improves Ankylosing Spondylitis assessment A new study has shown that low-dose computed tomography (LD-CT) is more sensitive than X-rays for monitoring

Presentation shows that healthcare costs for patients with a primary headache diagnosis cost four times more than a healthy patient due to comorbidities

Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000. This compares with the annual average healthcare cost of

Imaging with new biomarker tracks tumor progression, response to brain cancer treatment

UT Southwestern Medical Center researchers have developed an MRI-based method that can track the state and progression of a common type of genetically-mutated brain cancer. The study showed that 2HG is an excellent biomarker for tracking certain gliomas with IDH mutations and also can provide a diagnosis when neurological risk from surgery is too high,

electroCore’s bioelectric medicine, nVNS, successfully treats menstrual migraine

A paper in the Journal of Headache and Pain found that electroCore’s non-invasive vagus nerve stimulation treatment (nVNS), gammaCore, reduced menstrual and menstrual-related migraine attacks by more than a third, with 40% of the patients experiencing a reduction in migraine frequency of 50% or more. Menstrual migraine/menstrual-related migraine is one the most common categories of migraine in

New model for stroke care brings the hospital to the patient

In the U.S., the 2015 rate of stroke incidence was just under 800,000 people a year. A particularly disturbing contribution to this statistic is the increasing number of strokes among those aged 50 to 55, which has resulted in a corresponding increase in hospitalizations. With these changes, stroke is an increasingly important topic of concern

The Journal Headache reports that electroCore’s nVNS is an effective bioelectric medicine for episodic cluster headache

In a multi-centered, sham-controlled study conducted in the U.S., episodic cluster headache patients using the gammaCore non-invasive vagus nerve stimulation device (nVNS) had a significant and clinically meaningful benefit within 15 minutes of the treatment of the attack, as compared with the sham treatment, and that this benefit was sustained for over an hour. The

Non-invasive vagus nerve stimulation reduces frequency of migranes

A new sham-controlled pilot study on non-invasive vagus nerve stimulation (nVNS), recently published in Neurology, has found that nVNS therapy can reduce the number of headache days per month for chronic migraine patients. The study also found that patients who remained on nVNS therapy for longer periods of time enjoy progressively larger decreases in headache.

New technique could revolutionize surgical treatment of epilepsy

Scientists at the University of Exeter have developed a pioneering new technique that could revolutionize the surgical treatment of epilepsy. The team of scientists, led by Dr. Marc Goodfellow and Prof. John Terry, have developed the ground-breaking new method that can identify the specific regions of the brain that trigger seizures in people with epilepsy.

ElectroCore’s nVNS demonstrates efficacy in preventing cluster headache and menstrual migraine

The results of two studies, presented at the American Headache Society (AHS) Science Meeting last weekend in San Diego, show that using electroCore’s non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore, is effective at preventing both cluster headache and menstrual migraine. Cluster headache is considered one of the most painful conditions known to medical science with